OTC · CIK 0001583771
HEPA Hepion Pharmaceuticals, Inc.
Insider trading from SEC Form 4. Last filing 11 d ago. Close $0.12 on Oct 9, 2026, +243% from the 52-week low and -4% from the high.
Hepion Pharmaceuticals, Inc. (HEPA) has 7 SEC Form 4 filings on file from 5 insiders, the latest filed on Oct 2, 2026. In the last 90 days insiders made 1 open-market buy worth $10k and 0 open-market sells worth $0, net +$10k.
5 open-market trades have been scored at HEPA. The newest: Danina Fisher (director) bought $10k of stock on Sep 29, 2026, filed Oct 2, 2026, scored 23 (weak). The largest of the 5 shown: Vincent S LoPriore (Executive Chairman) bought $250k on Apr 21, 2026, scored 64 (notable). 4 insiders bought within 14 days of each other around Apr 21, 2026.
HEPA closed at $0.12 on Oct 9, 2026, 243% above its 52-week low and 4% below its 52-week high.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Hepion Pharmaceuticals, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 23Weak | Danina Fisher director buy | $10k 200,000 shares | - | - | |
| 53Moderate | Sireesh Appajosyula director buy | $50k 1,250,000 shares | - | +14% from low-90% from high | |
| 63Notable | Gary S. Stetz Interim CEO buy | $50k 1,250,000 shares | - | +14% from low-90% from high | |
| 64Notable | Vincent S LoPriore Executive Chairman buy | $250k 6,250,000 shares | - | +14% from low-90% from high | |
| 53Moderate | Michael J. Purcell director buy | $50k 1,250,000 shares | - | +14% from low-90% from high |
Transactions
Every row filed, 9 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 29, 2026 | Danina Fisher director | POpen-market purchase Common Stock | +200,000 | $0.05 | $10k | 200,000 | 11 d ago |
| Sep 29, 2026 | Danina Fisher director | POpen-market purchase Warrantsderivative | +200,000 | $0.00 | $0 | 200,000 | 11 d ago |
| Sep 3, 2026 | Vincent S LoPriore Executive Chairman | POpen-market purchase Warrantsderivativeindirect: By Gravitas Capital LP | +12,500,000 | $0.00 | $0 | 22,500,000 | 29 d ago |
| Aug 19, 2026 | Michael J. Purcell director | AGrant or award Stock Optionsderivative | +299,000 | $0.00 | $0 | 299,000 | 33 d ago |
| Apr 21, 2026 | Sireesh Appajosyula director | POpen-market purchase Common Stock, par value $0.0001 per share | +1,250,000 | $0.04 | $50k | 1,250,000 | Apr 27, 2026 |
| Apr 21, 2026 | Gary S. Stetz Interim CEO | POpen-market purchase Common Stock, par value $0.0001 per shareindirect: See Footnote | +1,250,000 | $0.04 | $50k | 1,250,000 | Apr 27, 2026 |
| Apr 21, 2026 | Vincent S LoPriore Executive Chairman | POpen-market purchase Common Stock, par value $0.0001 per shareindirect: By Gravitas Capital LP | +5,000,000 | $0.04 | $200k | 5,000,000 | Apr 27, 2026 |
| Apr 21, 2026 | Michael J. Purcell director | POpen-market purchase Common Stock, par value $0.0001 per share | +1,250,000 | $0.04 | $50k | 1,250,000 | Apr 27, 2026 |
| Apr 21, 2026 | Vincent S LoPriore Executive Chairman | POpen-market purchase Common Stock, par value $0.0001 per shareindirect: By Invictus Capital Advisors Pension Plan | +1,250,000 | $0.04 | $50k | 6,250,000 | Apr 27, 2026 |
Insiders
Everyone who has filed a Form 4 here.
- Sireesh Appajosyulacoo, officer, director, ceo
- Danina Fisherdirector
- Vincent S LoPrioreExecutive Chairman
- Michael J. Purcelldirector
- Gary S. StetzInterim CEO
Questions about HEPA
Answered from the filings on this page, as of the latest one.
Are insiders buying HEPA?
As of Oct 2, 2026, SEC Form 4 filings show 1 open-market buy worth $10k by 1 insider and 0 open-market sells worth $0 by 0 insiders at Hepion Pharmaceuticals, Inc. in the last 90 days, net +$10k. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade HEPA on the open market?
Danina Fisher (director) bought $10k of HEPA on Sep 29, 2026 and filed the Form 4 on Oct 2, 2026. InsiderTell scored 23 (weak).
How many insiders file Form 4 at Hepion Pharmaceuticals, Inc.?
5 people have filed a Form 4 at Hepion Pharmaceuticals, Inc., among them Sireesh Appajosyula (COO, director and CEO), Danina Fisher (director), Vincent S LoPriore (Executive Chairman). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.